Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of SNS812 in Participants With Mild to Moderate COVID-19

NCT05941793 is registered in ClinicalTrials.gov with Oneness Biotech Co., Ltd. as lead sponsor.

NCT NCT05941793
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05941793 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of SNS812 in Participants With Mild to Moderate COVID-19
Lead sponsor
Oneness Biotech Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
September 11, 2023
Completion date
August 12, 2024
Enrollment
135 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

mild to moderate covid-19